In IRB-approved clinical validation trials conducted between 2013 and 2017, Tata Memorial Hospital and Olive View-UCLA Medical Center demonstrated concordance of the Navya Cancer Data Model matched evidence-based treatment options with multidisciplinary tumor board decisions and NCCN Guidelines. (SABCS 2014, ASCO 2016, SABCS 2017).
In a recent study co-authored by faculty at Memorial Sloan-Kettering Cancer Center and presented at ASCO 2021, the Navya Cancer Data Model enabled cancer experts to review clinical record summaries in an average time of <4 minutes and make a treatment decision with ease in 95.7% of cases. Other clinical validations and patient impact studies are available on our Scientific Conferences page.
In a separate study co-authored by two leading cancer providers in India (Tata Memorial Hospital and The National Cancer Grid) and presented at ASCO 2017, 73% of patients shared the Navya "Structured Treatment Options" with their treating oncologists, and 78% received the recommended treatments.
In a study co-authored by the same two groups and presented at ASCO 2020, the online services provided by Navya resulted in 50% of patients changing their treatment decision from non-guidelines compliant to guidelines compliant care.